Chemical Structure : AIK3a305
Catalog No.: PC-26254Not For Human Use, Lab Use Only.
AIK3a305 (AIK3-305) is an allosteric inhibitor of Jmitogen-activated protein kinases (MAPK), particularly JNK, and a potent and selective, orally available inhibitor IL-1β release in human monocyte-derived macrophages with IC50 of 28 nM.
Bulk size, bulk discount!
Welcome credit card payment!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
AIK3a305 (AIK3-305) is an allosteric inhibitor of Jmitogen-activated protein kinases (MAPK), particularly JNK, and a potent and selective, orally available inhibitor IL-1β release in human monocyte-derived macrophages with IC50 of 28 nM.
AIK3a305 does not interfere expression levels of IL-1α, IL-2, IL-6, IL-8 or GM-CSF.
AIK3a305 shows direct biophysical interactions to p38α MAPK with SPR KD of 12 nM.
AIK3a305 (10-20 mg/kg) inhibits IL-1β secretion in LPS endotoxic shock model in male BALB/c mice.
AIK3a305 selectively inhibited LPS- and palmitate-induced IL1β expression in macrophages, while protecting hepatocytes from intracellular lipid accumulation and lipoapoptosis.
AIK3a305 attenuated disease progression in animals fed either a HFD or a CDAA diet, as evidenced by improved liver histopathology, including reduced steatosis and inflammation, in preclinical models of MASLD.
| M.Wt | 532.05 | |
| Formula | C26H30ClN3O5S | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
1. Berlana Á, et al. Biomed Pharmacother. 2026 Feb;195:119052.
2. Zegarra-Valdivia JA, et al. Geroscience. 2022 Aug;44(4):2243-2257.
3. Carrasco E, et al. Eur J Med Chem. 2021 Nov 5;223:113620.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright